Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Investing.com -- The US Food and Drug Administration (FDA) has given limited approval to a new mRNA COVID-19 vaccine developed by Moderna (NASDAQ:MRNA), intended for high-risk populations. The announcement was made by Health and Human Services (HHS) Secretary Robert F. Kennedy.
The new vaccine, which utilizes a smaller protein, is similar to the existing mRNA vaccine. Moderna has agreed to conduct a true placebo-controlled trial of this vaccine. The FDA has committed to closely monitor the trial and collect data on every adverse outcome, not just those outcomes that are expected.
The agency has pledged to scrutinize all aspects of the trial, affirming its commitment to uphold the highest scientific standards and common sense in its oversight. This approach aims to ensure the safety and efficacy of the new vaccine for high-risk populations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.